Always on: Cannabis and mushroom extraction company Pure Extracts Technologies (WKN A2QJAJ / CSE PULL) drives entry into the market for psychedelic medicine. Now the company has presented the roadmap for how it should proceed in the next eight months or more.
In cooperation with the renowned Toronto Institute of Pharmaceutical Technology (TIPT), the detailed planning for a study on the formulation and manufacture of oral tablets, capsules and a psilocybin-based nasal gel was completed. The study is led by Dr. Alexander MacGregor, Dean of the Faculty, Distinguished Professor of Biopharmaceuticals and currently President of TIPT.
Pure Extracts Technologies sets out exactly which milestones the study is to achieve – from the procurement and purchasing of medical ingredients, auxiliary materials and packaging materials to raw material testing, formulation and manufacturing process development and stability testing to the production of clinical batches, quality control tests for the release of active ingredients and the shipping of the clinical batches to the CRO (Contract Research Organization).
The study focuses on the formulation, manufacture and clinical bioavailability tests of fast-acting psilocybin dosage forms that could be used in future clinical efficacy tests both by Pure Extracts themselves and by their customers in the pharmaceutical industry.
As Pure Extracts CEO Ben Nikolaevsky explains, this is how you use the time that passes anyway until the company receives the desired Dealer’s License (we reported.) Https://goldinvest.de/cannabis/4154- license application-pure-extracts -take-next-step-in-direction-psychedelics receive. In this way, you will be well prepared for the step into the psychedelics sector and will already have advanced knowledge of psilocybin and the novel delivery mechanisms associated with it, according to Nikolaevsky.
We really like the company’s methodical and systematic approach, and we’re excited to see the progress Pure Extracts can make in the field of psychedelic medicine this year. At the same time, the company also has extraction in the cannabis / CBD sector and functional mushrooms as additional pillars, which in our opinion makes the company unique. Of course, Pure Extracts is a high risk speculation, the odds are, we believe, but also high.
Subscribe to our free newsletter: https://goldinvest.de/newsletter
Follow us on Youtube: https://www.youtube.com/user/GOLDINVEST
In accordance with Section 34b WpHG and Section 48f Paragraph 5 BörseG (Austria), we would like to point out that partners, authors and / or employees of GOLDINVEST Consulting GmbH can hold shares in Pure Extracts Technologies and thus a conflict of interest could exist. We cannot rule out that other stock market letters, media or research firms will discuss the values we have discussed during the same period. Therefore, symmetrical generation of information and opinions can occur during this period. Furthermore, there is a consulting or other service contract between GOLDINVEST Consulting GmbH and a third party in the issuer’s warehouse (Pure Extracts Technologies), which creates a conflict of interest, especially since this third party grants GOLDINVEST Consulting GmbH for a fee for reporting Pure Extracts Technologies rewards. This third party may also hold, sell or buy shares in the issuer and would benefit from an increase in the price of Pure Extracts Technologies shares. This is another conflict of interest.
PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section. PERSONAL-FINANCIAL.COM AG is not responsible for content that is recognizably posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.